Results 41 to 50 of about 457,015 (304)

Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models [PDF]

open access: yes, 2010
Chimpanzees represent the only animal model for studies of the natural history of hepatitis C virus (HCV). To generate virus stocks of important HCV variants, we infected chimpanzees with HCV strains of genotypes 1-6 and determined the infectivity titer ...
Bukh, Jens   +11 more
core   +1 more source

Immunological response of Hepatitis B Virus Surface Antigen in HBV Mono and HBV/HDV Co-infection

open access: yesPakistan Journal of Medicine and Dentistry
Hepatitis B virus (HBV) can evolve under selection pressure exerted by drugs and host immunity, resulting in the accumulation of escape mutations that can affect the drug or the immune activity.
Mehwish Sajjad   +3 more
doaj   +1 more source

Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report

open access: yesJournal of Medical Case Reports, 2019
Background Although several cases of hepatitis B virus reactivation have been described in patients with a history of hepatitis B virus infection while undergoing treatment for hepatitis C virus infection with direct acting antivirals, the question of ...
Luca Foroghi Biland   +10 more
doaj   +1 more source

Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas [PDF]

open access: yes, 1996
This paper uses meta-analysis of published data and a deterministic mathematical model of hepatitis B virus (HBV) transmission to describe the patterns of HBV infection in high endemicity areas.
A. J. Hall   +20 more
core   +2 more sources

The enzymes LSD1 and Set1A cooperate with the viral protein HBx to establish an active hepatitis B viral chromatin state [PDF]

open access: yes, 2016
Indexación: Web of ScienceWith about 350 million people chronically infected around the world hepatitis B is a major health problem. Template for progeny HBV synthesis is the viral genome, organized as a minichromosome (cccDNA) inside the hepatocyte ...
Alarcon, V   +9 more
core   +2 more sources

Phosphatidylinositol 4‐kinase as a target of pathogens—friend or foe?

open access: yesFEBS Letters, EarlyView.
This graphical summary illustrates the roles of phosphatidylinositol 4‐kinases (PI4Ks). PI4Ks regulate key cellular processes and can be hijacked by pathogens, such as viruses, bacteria and parasites, to support their intracellular replication. Their dual role as essential host enzymes and pathogen cofactors makes them promising drug targets.
Ana C. Mendes   +3 more
wiley   +1 more source

Prevalence of Hepatitis B, C and D Infections in Preoperative Patients at a Tertiary Hospital in Southern Nigeria

open access: yesSokoto Journal of Medical Laboratory Science, 2023
Patients going for surgical operations are required to be screened for hepatitis B virus (HBV) and hepatitis C virus (HCV) infections among other transmissible infections.
Joseph E. Udosen , Euphoria C. Akwiwu , Dennis A. Abunimye , Utibe-Abasi Felix , David U. Akpotuzor , Josephine O. Akpotuzor
doaj  

MOLECULAR-EPIDEMIOLOGICAL FEATURES OF HEPATITIS B VIRUS

open access: yesИнфекция и иммунитет, 2016
. Hepatitis B virus is a serious issue of public health services all over the world, particularly in Russia and its regions. The cause can be determined due to its higher incidence rate in different ethnic and geographical groups, variety of ...
V. V. Gerasimova   +3 more
doaj   +1 more source

The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature [PDF]

open access: yes, 2019
The second-generation of direct-acting antiviral agents are the current treatment for chronic viral hepatitis C infection. To evaluate the regression of liver fibrosis in patients receiving this therapy, liver biopsy remains the most accurate method, but
Alexescu, Teodora G   +12 more
core   +3 more sources

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

Home - About - Disclaimer - Privacy